

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

ROS1 diagnostic testing is not yet established in England. Restricting testing to patients with a diagnosis of adenocarcinoma was seen as a potential inequality in the consideration crizotinib for the treatment of ALK+ NSCLC. Patients with adenocarcinoma or non-squamous advanced lung cancer and selected squamous tumours for non-smokers would be considered appropriate for ROS1 testing. This testing protocol would support equitable access to patients who would benefit from crizotinib.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee should ensure that the evidence and its recommendations do not exclude any relevant patients or protected groups (under the equalities legislation) because of diagnostic testing.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): Helen Knight

Date: 26/05/2017